Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?

BJU International
Tom PicklesScott Tyldesley

Abstract

What's known on the subject? and What does the study add? Previous reports, with small numbers of patients, have described the problem of incomplete testosterone suppression (>1.1 or 1.7 nmol/L) with LHRH agonists. Various predisposing factors have been suggested: different drug agents and patient factors such as age, pretreatment testosterone levels and weight. Such incomplete testosterone suppression has been shown in one small report to be associated with increased PSA failure rates and in another report in those with metastases, with worse survival. This study used testosterone assays that are more accurate at low levels than those used in most previous reports in a large dataset of 2196 men, and confirmed incomplete testosterone suppression (breakthrough) rates >1.7 nmol/L of 3.4% and >1.1 nmol/L of 6.6%. We showed that younger age was strongly associated with the risk of breakthrough, with a minor effect of increasing body mass index. Repeated breakthroughs were more common (16%) in those who had already had one breakthrough. Interim measures of cancer control (PSA kinetics during LHRH therapy) were inferior in those with a breakthrough, and those with breakthroughs between 1.1 and 1.7 nmol/L had worse long-term biochemic...Continue Reading

References

Jan 1, 1992·Scandinavian Journal of Urology and Nephrology·H F Røhl, H P Beuke
Sep 7, 2000·International Journal of Radiation Oncology, Biology, Physics·J CrookM Abdolell
Jul 4, 2001·The Journal of Urology·M R Smith, F J McGovern
Aug 15, 2001·Urology·G J Bubley
Jul 21, 2005·International Journal of Radiation Oncology, Biology, Physics·Charles M LudgateGary Steinhoff
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maha HussainUNKNOWN Southwest Oncology Group Trial 9346 (INT-0162)
May 12, 2009·The American Journal of Cardiology·José G Díez, Marc Cohen
Aug 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles J Ryan, Donald J Tindall

❮ Previous
Next ❯

Citations

Oct 30, 2015·Expert Opinion on Drug Metabolism & Toxicology·Laurence Klotz
Jun 27, 2015·Asian Journal of Andrology·Judd W Moul
Jan 11, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Tomokazu KimuraHideyuki Akaza
Jan 11, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Masaki Shiota
Jan 7, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mhd Y Al-MarrawiJoseph J Drabick
Jan 11, 2018·Endocrine-related Cancer·Clovis Boibessot, Paul Toren
Mar 15, 2019·Cancer Chemotherapy and Pharmacology·Masaki ShiotaMasatoshi Eto
Aug 8, 2015·Der Urologe. Ausg. A·C-H OhlmannC Protzel
May 9, 2021·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Almudena ZapateroFelipe A Calvo
Sep 24, 2021·Aktuelle Urologie·Stefan ZastrowHenrik Suttmann

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.